Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

our co-therapy trials in the U.K. and our sarcoma study in the U.S. We believe that the results from these trials will allow us to broaden our Phase II clinical trial program and choose a pivotal trial path. As well, we believe that the NCI will commence enrollment in its two sponsored clinical trials.

We expect to produce REOLYSIN(R) for our clinical trial program throughout 2008. We believe we will complete our 100-litre scale up studies and will continue our examination of a lyophilization (freeze drying) process for REOLYSIN(R).

We continue to estimate, based on our expected activity for 2008 that our average monthly cash usage will be $1,660,000 per month (see "Liquidity and Capital Resources").

Recent 2008 Progress

Clinical Trials - Positive Interim Results

In April, we announced positive interim results and completion of the dose escalation portion of our U.K. combination REOLYSIN(R) and carboplatin/paclitaxel trial. Four of the first eight patients treated in the study to date have a diagnosis of carcinoma of the head and neck. All three head and neck patients evaluated to date have had excellent clinical and radiological responses without appreciable toxicity. Preliminary assessment after recruitment of the first two cohorts has suggested that patients with head and neck carcinomas represent a group of patients for whom the combination of carboplatin/paclitaxel and REOLYSIN(R) may prove effective.

In the first cohort, the patient with head and neck cancer received 8 cycles of treatment (the maximum allowed) and achieved a clinical complete response. In the second cohort, the two patients with head and neck cancers with widespread disseminated disease have each received seven cycles of treatment to date and both have achieved significant partial responses. Two of the three patients, including the patient with the clinical complete response, had previously received cisplatin/5-FU treatment and all three had prev
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... webinar series is designed to introduce cutting ... inform users and partners of platform upgrades. ... and benefits; empowering users in their quest ... powerful tools. , According to SoundConnect’s Marketing ...
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced ... treasurer for the American Society for Reproductive Medicine (ASRM), ... research in reproductive medicine. In his new role ... the executive board and will have a voice in ... has actively supported ASRM since 1984 when he joined ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... YORK, October 25 XTL Biopharmaceuticals,Ltd. (NASDAQ: ... has,entered into definitive agreements with institutional investors relating ... million in gross proceeds of,ordinary shares, represented by ... transaction are Perceptive Life Sciences Fund, Quogue,Capital LLC, ...
... Innovative Fall Detection ... and Prevention System, FALLS CHURCH, ... in the elderly. The National Institute on Aging (NIA),part of the ... Business Innovation Research grant entitled,"Non-Intrusive Locomotion and Gait Stability Analysis Monitoring ...
... October 25 Glycominds Ltd., a,bio-diagnostics company specializing ... autoimmune diseases and cancer, announced today,entering into a ... an,NCI designated cancer center to develop a new ... very pleased to work with FCCC on this ...
Cached Biology Technology:XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 2XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 3Leading Edge Research Underway in Fall Prevention for Seniors 2Leading Edge Research Underway in Fall Prevention for Seniors 3Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests 2
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... As part of our commitment to offering ... to announce the release of a new reader that ... workforce data that they need. The Atlas ... existing readers. Many such devices have serious shortcomings when ... Older models force users to navigate numerous complicated steps ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... 2012 - The American Federation for Aging Research (AFAR) ... collaboration among young scientists from different scientific disciplines, to ... Alzheimer,s disease. Known as The Collaborative Research Awards Program ... The Rosalinde and Arthur Gilbert Foundation and the Diane ...
... to understand why some people excel whether as ... discovered that these outstanding performers have unique brain characteristics ... published in May in the journal Cognitive Processing ... three measures the Brain Integration Scale, Gibbs,s Socio-moral ...
... ancient reserves of methane gas seeping from the melting Arctic ... already knew: As the permafrost thaws, there is a release ... The trick was figuring out how much, said Chanton, ... University. The four-member team whose findings were published ...
Cached Biology News:Grant program to spur new research on Alzheimer's disease by encouraging collaboration 2Research breakthrough: High brain integration underlies winning performances 2Research breakthrough: High brain integration underlies winning performances 3Research breakthrough: High brain integration underlies winning performances 4Research breakthrough: High brain integration underlies winning performances 5Study: Seeping Arctic methane has serious implications for Florida coastline 2
... used gasketed gel trays. Turn the tray 90 degrees ... back and run the gel - its as simple ... tray is UV transparent. Each tray accommodates two comb ... one in the center. This allows you the option ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
... Ascent is a dedicated fluorometer ... all kinds of assays in ... for clinical applications. Cell biology, ... all important application areas. Robot-friendly ...
... of Class II Biological Safety Cabinets ... to the world's highest safety standards. ... cabinets cannot be adjusted out of ... noise and arm rest ensure safety ...
Biology Products: